#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1635

Examiner : Louis V. Wollenberger Applicant : Nariyoshi Shinomiya et al.

Appln. No. : 10/599,327 Filing Date : March 12, 2007

Confirmation No. : 7013

For : *c-met* siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL

GROWTH, INVASION AND TUMORIGENICITY

#### **DECLARATION UNDER 37 C.F.R. § 1.131**

We, the undersigned, do hereby declare as follows:

- 1. We are the co-inventors of the claims of the above-identified patent application.
- 2. The invention as defined in claims 1-12, 14-17, and 38 was conceived of and actually reduced to practice prior to January 6, 2003. The invention as defined in claims 13, 18-20, and 48-50 was conceived of and actually reduced to practice prior to July 7, 2003.
- 3. Evidence of our conception and reduction to practice of the invention as defined in claims 1-20, 38, and 48-50 is provided in the form of experimental data from the laboratory notebook of Nariyoshi Shinomiya, one of the named inventors (attached hereto as Exhibit A1-A10). More specifically, these laboratory notebooks show our development of an RNAi molecule directed to c-met:
  - a) in the cancer cell lines DU-145, SK-LMS-1, DA3, and M114 (Exhibit A1);
  - b) using siRNA expression vector pSilencer 1.0-U6 for human c-met (Exhibit A2 and A4);
  - c) targeting human c-met sequence 221, the target of SEQ ID No. 15 (Exhibit A3);
  - d) using pShuttle vector (Exhibit A5);

**Applicant** 

Nariyoshi Shinomiya et al.

For

.

c-met siRNA ADENOVIRUS VECTORS INHIBIT CANCER CELL

GROWTH, INVASION AND TUMORIGENICITY

Page

:

e) using an Ad5 viral vector (Exhibit A6 and A9);

f) using a stable transformant (Exhibit A7 and A8); and

g) in DBTRG glioblastoma cells (Exhibit A10).

4. The documents attached as Exhibit A1-A10 were prepared contemporaneously with our conception and reduction to practice.

5. The acts referred to in the preceding paragraphs occurred in the United States.

6. The undersigned hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Sections 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date

George F. Vande Woude

N. Strinomiya

September 26, 2009


Date


Nariyoshi Shinomiya

- KPMI 1640 + 57/6 FBS QD4-145 (-160°C stock (/10/023) (+1 1 /2 pex/strap) 3555 @ ISK-LMS-1 -- DMEM-+-101/6/F&BS - BONDERS (#11965-090) (+1%-pan/strep) (Passage 2) Arce - DMEN + 10% Calf Derum (D) b43 (-160°C strok = 3/25/01) (+1/2 par/strep) ®MILE (-160°C Stock=10-26-01) LINEM + 10% Cally Serum (++4-pon/strop) Tetal Booking Server although eding & Cell presentation mulica \* 57. EBS-RPM21640 (cat 7005/1875-093 -7185-15 ml - 1975 - Brand 78.17.14.25 28.20.14 Cat Hr. 11465-199 1510 : 1140 <del>3</del>=7 403 300L 1/3 3 ml PMEM 257 int Cell preservation-wadie DMSO PAINLAND A HILL D1180-2-m2 4708 20 m FBS Some DMEM F3MV LRPML-73 W

EXHIBIT A1

Transformation of psilences" 1.0-U6 voito-	
The total angelout Energy	
property of the second	
5722-30fridoftibe on 2000 2000	
72078092P01A	
Man Was a series of the series	
Shaking inaubitting (07° e., 250 ppm)	
plate on amples plate (+10,44, comples)	
	torri ota a salada g
(continued)	or English
180/18 - ESCETTIZE DE TERMANY PAR COLO	
780/10 -> colonies are too many (can not be placed up)	
180/18 - ESCETTIZE DE TERMANY PAR COLO	
780/10 -> colonies are too many (can not be placed up)	
780/10 -> colonies are too many (can not be placed up)	
780/10 -> colonies are too many (can not be placed up)	
780/10 -> colonies are too many (can not be placed up)	
780/10 -> colonies are too many (can not be placed up)	
780/10 -> colonies are too many (can not be placed up)	
780/10 -> colonies are too many (can not be placed up)	





D. Sequencing 172 (1428-0) #16 ("16-3) 162 (162-2) 26-196-17 #22/ (#22 -2) F 25 WY WEE SO Wisside of Legitory lation with initia

7 Stock (250 pmcl/pl) -20°C

#### siRNA hairpin template sequences for human c-met RNAi

#### A. Criteria of Sequence Selection

- 1. 21mer that start with AA
- 2. GC content between 45-55%
- 3. No more than three consecutive T or G nucleotides can be present anywhere in the hairpin template sequences
- 4. The targeted region is selected from a given cDNA sequence beginning 50 to100 nt downstream of the start codon. (5' or 3' UTRs and regions nearby the start codon are avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex.)
- 5. Blasted selected sequences against Genbank
- 6. Nucleotide cross-match (no more than 17, much less would be better)
- 7. Start with AAG (for cloning into pSilencer 1.0-U6 vector system; RNA transcription begin with G, but according to the company's information a +1 G is not required.)

8. A pair of template sequences is as follows:

Sense Loop Antisense

Template 1: 5'-N(19)-TTCAAGAGA-N(19)-TTTTTT-3' (53mer)
Template 2: 3'-CCGG-N(19)-AAGTTCTCT-N(19)-AAAAAATTAA-5' (61mer)

paI EcoRI

Target sequence (18) AAGACCTTCAGAAGGTTGCTG

<u>Siast search</u> (in new window) Position in gene sequence: 415

GC content: 47.6%

siRNA Sense strand: GACCTTCAGAAGGTTGCTGTT siRNA Antisense strand: CAGCAACCTTCTGAAGGTCTT

#16-1: 5'-GACCTTCAGAAGGTTGCTG-TTCAAGAGA-CAGCAACCTTCTGAAGGTC-TTTTTTT-3' #16-2: 3'-CCGG-CTGGAAGTCTTCCAACGAC-AAGTTCTCT-GTCGTTGGAAGACTTCCAG-AAAAAATTAA-5' #16-2: 5'-AATTAAAAAA-GACCTTCAGAAGGTTGCTG-TCTCTTGAA-CAGCAACCTTCTGAAGGTC-GGCC-3'

Target sequence(62) AAGCCAGATTCTGCCGAACCA

<u>Blast search</u> (in new window)
Position in gene sequence: 1236

GC content: 52.4%

SIRNA Sense strand: GCCAGATTCTGCCGAACCATT
SIRNA Antisense strand: TGGTTCGGCAGAATCTGGCTT

#62-1: 5'-GCCAGATTCTGCCGAACCA-TTCAAGAGA-TGGTTCGGCAGAATCTGGC-TTTTTT-3'
#62-2: 3'-CCGG-CGGTCTAAGACGGCTTGGT-AAGTTCTCT-ACCAAGCCGTCTTAGACCG-AAAAAATTAA-5'
#62-2: 5'-AATTAAAAAA-GCCAGATTCTGCCGAACCA-TCTCTTGAA-TGGTTCGGCAGAATCTGGC- GGCC-3'

Target sequence 76: AAGCGCGCCGTGATGAATATC

Biast search (in new window)
Position in gene sequence: 1417

GC content: 52.4%

SIRNA Sense strand: GCGCGCCGTGATGAATATCTT SIRNA Antisense strand: GATATTCATCACGGCGCGCTT

#76-1: 5'-GCGCGCCGTGATGAATATC-TTCAAGAGA-GATATTCATCACGGCGCGC-TTTTTTT-3'
#76-2: 3'-CCGG-CGCGCGCGCACTACTTATAG-AAGTTCTCT-CTATAAGTAGTGCCGCGCG-AAAAAATTAA-5'
#76-2: 5'-AATTAAAAAA-GCGCGCGTGATGAATATC-TCTCTTGAA-GATATTCATCACGGCGCGC- GGCC-3'

Target sequence (223) AAGTGCAGTATCCTCTGACAG

<u>Blast search</u> (in new window)
Position in gene sequence: 3310

GC content: 47.6%

siRNA Sense strand: GTGCAGTATCCTCTGACAGTT siRNA Antisense strand: CTGTCAGAGGATACTGCACTT

#221-1: 5'-GTGCAGTATCCTCTGACAG-TTCAAGAGA-CTGTCAGAGGATACTGCAC-TTTTTT-3'
#221-2: 3'-CCGG-CACGTCATAGGAGACTGTC-AAGTTCTCT-GACAGTCTCCTATGACGTG-AAAAAATTAA-5'
#221-2: 5'-AATTAAAAAA-GTGCAGTATCCTCTGACAG-TCTCTTGAA-CTGTCAGAGGATACTGCAC- GGCC-3'

# < Sequence confirmation of SiRNA gloswid >

#### Expression plasmids for c-met RNAi (final clones)

1. Mouse siRNA (host plasmid = mU6pro)

40 K K K K K K K K K K K K K K K K K K K	r francoe francostants 🗠	moone		
Target sequence No.	Position in gene sequence	Ligation of synthesized oligos & transformation	Sequence confirmation of the inserted oligos	Final clone #s
#57	950	finished	confirmed	#57-1, #57-2, #57-3
#60	988	finished	confirmed	#60-1, #60-4
#110	1839	finished	confirmed	#110-1, #110-2, #110-3
#120	1977	Very low transformation efficiency	-	**
#178	2762	finished	confirmed	#178-0, #178-1, #178-2

2. Human siRNA (host plasmid = pSilencer)

Target sequence No.	Position in gene sequence	Ligation of synthesized oligos & transformation	Sequence confirmation of the inserted oligos	Plasmid amplification for transfection
#16	415	finished	confirmed	#16-3
#62	1236	finished	confirmed	#62-2
#76	1417	finished	Wrong sequence	G0
#221	3310	finished	confirmed	#221-6

#red, #blue: plasmid clones were amplified and used for transfection Control plasmid: mU6pro = mU6#1, pSilencer = pSil#1

	- Mudest CM	CA-SI (MICHAILE)	24457474.S.S., JAS.	Ting. Strantis — Ting to the transfer of the second
A Part of the second	Buday - 320AXAD	ion allower from	-80°C <101/C	endere i i i i i i i i i i i i i i i i i i
€ :				erana eranada sastema ini jayan ya ya
	127 - 01/R UP 1	midday Ed	iksiist mikkun	
annannava				A. Arriba
			18 Starte Color	- Chalingas
				energia.
but con conse				energia kalka apatapa energia en en esperante en en esperante en en en esperante en
Ligati	on reaction (brief protocol)			· · · · · · · · · · · · · · · · · · ·
a. Sti	ick-ends (Cohesive Ends) Liç	ation		
	To an eppendorf tube add the	following:		
	5x ligase reaction buffer vector DNA	4 µL		Middle diseases are received to a con-
	insert DNA	3-30 fmol (2.5-25 ng) 9-90 fmol (7.5-75 ng)		months and a second production
	(total DNA	0.01-0.1 μg)		
	autoclaved distilled water	to 19 μL		
	T4 DNA Ligase	1 unit (in 1 µL)		. And the control of
	Final volume	20 μL		
2.	Mix gently. Centrifuge to bring	the contents to the bottom of the	ube.	000000000000000000000000000000000000000
3. A	Add 1 of 0 E M EDTA to in-	t least 5 min (30 min would be bett	er).	Adampaga amenin ing menggalan salah sa Salah salah sa
5.	Add 1 $\mu$ L of 0.5 M EDTA to ina Store the reaction at 4°C.	cuvate the enzyme.		
6.		reaction five-fold in autoclaved dis	tilled water and use it	
	to transform competent cells.		accined thereing forces from the	a de la compania de La compania de la co
	-			
	nt ends Ligation			
1.	To an eppendorf tube add the			
	5x ligase reaction buffer	4 μL		and the agreement and the control of
	vector DNA Insert DNA	15-60 fmol (25-250 ng)		
	(total DNA	45-180 fmol (75-750 ng) 0.1-1.0 μg)		and the second second second
	autoclaved distilled water	to 19 μL		
	T4 DNA Ligase	1 unit (in 1 uL)		
	Final volume	20 µL		
2.	Mix gently. Centrifuge to bring	the contents to the bottom of the	tube.	
3.	Incubate at 14°C for 16-24 hr.			
	Add 1 µL of 0.5 M EDTA to Ina	ctivate the enzyme.		
	Store the reaction at 4°C.			#
	vilute an aliquot of the ligation	reaction five-fold in autoclaved dis	tilled water and use it	Control of the Contro
ъ.	to transform competent cells.			

#### Design (restriction enzyme digestion & ligation)

#### **Murine c-met siRNA**

pShuttle (vector): XbaI/HindIII double digestion --> gel purification mU6pro (insert): HindIII/XbaI double digestion --> gel purification

XbaI = REact 2,  $37^{\circ}$ C, 1 hr HindIII = REact 2, 37°C, 1 hr

\*stick ends ligation (direction of the insert is reverse)

#### Human c-met siRNA

pShuttle (vector): KpnI digestion --> phenol extraction/ethanol precipitation EcoRV digestion --> gel purification


pSilencer (insert): KpnI/SmaI double digestion (30°C then 37°C) --> gel purification

 $KpnI = REact 4, 37^{\circ}C, 1 hr$ 

SmaI = Gene Choice buffer 4 (=REact 4), 30°C, 1 hr

EcoRV = Gene Choice buffer 2 (=REact 2), 37°C, 1 hr

\*blunt ends ligation (the same direction)



### < Western blot ~ Results>

D Control

3 HAR-protected

\* 50, 110 KOa - phosphorylation hands are two strong.

[New time Load 5749 protein

[Separate with 840 gel

Chilenovirus parification using Virapur > t:tre(opr/ml)Phi @ 0.161 0.135 1.195 (8×10/2)

Phi @ 0.161 0.135 1.195 (3×10/2)

pad@ ]->harvest tomorrow

pAd Q, Q = 300 pl end × 9 + 1 end = 5 - 80°C

**EXHIBIT A6** 

< Western blot - splittmofectant 34-LUS-1 204-145> primary. Lb o protein (c-Met (c2)) /22000 p-Adda (AC/S) /25000

2 nday 16 /d-rabbit /=1000 d-Mouse /= 4000

2019 was Loaded in each Lame (both SKand DU)

The State of the State of 

WE TO AND CONTRACTOR

1.00 the second

641 3

C-Met Downregulation is also observed in DN-145 cells

## < Histology of the remnant livers >

	Sample name	Serial number	Sample name
GVW-4001	C 12h-1		
4002	C 12h-2		H 12h-2
4003	C 12h-3	4018	H 12h-3
4004	C 24h-1	4019	H 24h-1
4005	C 24h-2	4020	H 24h-2
4006	C 24h-3	4021	H 24h-3
4007	C 36h-1	4022	H 36h-1
4008	C 36h-2	4023	H 36h-2
4009	C 36h-3	4024	H 36h-3
4010	C 48h-1	4025	H 48h-1
4011	C 48h-2	4026	H 48h-2
4012	C 48h-3	4027	H 48h-3
4013	C 72h-1	4028	H 72h-1
4014	C 72h-2	4029	H 72h-2
4015	C 72h-3	4030	H 72h-3

Difference in the milatic indices ?

4001 - normal, hard to find mitalicells 4002 ~ small vacually. - pleeding inside the liver, hypolone-like changes

4004 - many valueles @

small vacuales @ (around the vein increased es)

voucles (9)

small rawallo

small vacubles. Hormal

small vacuallas)/mitatic allegy

4011 ~ vamoles@/mitaticalle, occasionally

4013 - mitalicalls 1 ~3/HPF

4015

4016 - many bleeding sites

4017 — small ve melio@

4019 ~ vaivoles @

4022 - vacuoles@ depends on the pethon Mitoris occasionally

4023 — vamollo@, Mixos occasionally,

4024 — vacuolood hyalino nevosis 4025 — inflammation! 4025 — vacuolood Milesis 203/HPF

4026 mixosis 2-3/48F

4029-

4028 ~ Milesis 2~3/HIE

6029~

6030 m

EXHIBIT A8 Page 1 of 2

< Western blot - siRNA stable transformant > Expression of EGAR.

[] SK-LMS-1 x, M, Q, 1-1, 2-1, 8-), 4-6, 5-6, 5-6, 1-k, 4-f, x (20/19 protein) DN-445

x, M, O, 1-c, 1-d, 1-l, 2-l, 3-e, 3-h, 4-f, 4-h, x

1st Ab = d-EGTR 1=1000 241 BL = X-PALDIT 1= 2000

Results ~


() 5K-LØ5-I e earr G 011-145

in SK-LMS-1 - expression of EGFIC varies a also correlates well with proliferative activity

In DU-145 - normarbable changes in the EGFIC lively

EXHIBIT A8

< Cell scattering activity ~ 1543 als >



10 mg/ml HGF was added to each well (1230 am. ~ 204)

Charge state rirus production \_\_pAd(E)
 TIPS x 5 flasks — almost all colls and detached from the bottom and floated as single cells.
 Virapir kit

00 260 00280 26928070010, 2.041 0.029 1.394

particle number =  $0.04/\times 50 \times 1.1 \times 10^{12} = 2.3 \times 10^{12} \text{ copu/ml}$ )


500  $\mu$  each  $\times$  8 tubes +  $\phi$  additional tube  $\rightarrow -80^{\circ}\text{c}$ (>  $(000 \mu)$ )

Stock

< RT-PCK results> \* after 1/3 pH ← h ИСБ (539bp) no-hH9F expression in said control mice. no remarbable changes in terms of time works  $\leftarrow mHQT$ (365 bg) tom Quadin (376 bp)

< DBTRG cells siRNA adv. infect => HOF stimulation>

## siRNA suppresses Met phosphorylation



e Met is down regulated in pAdD infected cells

Not phosphorylation is also significantly suppressed in pAdD infected
ealls

But regarding to she Akt-phosphorylation & PUJO2 MAPK phosphorylation
strong phosphorylation bonds were observed from the boginning
(before HIFT stimulation